Gardasil 9 consists of HPV proteins, Types 6, 11, 16, 18, 31, 33, 45, 52, and 58, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, Polysorbate 80, sodium borate, and water for injection.
Gardasil 9 helps protect girls and women ages 9 to 45 against cervical, vaginal, vulvar, and anal cancers and genital warts caused by 9 types of HPV.
It also is indicated to help protect boys and men ages 9 to 45 against anal cancer and genital warts caused by those same HPV types.
Each dose of Gardasil 9 is 0.5-mL and is administered intramuscularly only.
The Age Recommended Regimen Schedule:
- 9 through 14 years 2-dose 0, 6 to 12 months
- 15 through 45 years 3-dose 0, 2, 6 months
7 types of HPV can lead to certain cervical cancers. The cervix is the lower part of the uterus that connects to the vagina.
When a female is infected with these types of HPV, and the virus doesn't go away on its own, abnormal cells can develop in the cervix. If these abnormal cells are not found early through routine cervical cancer screening and treated, then cervical cancer can develop.
Many females with cervical cancer were probably exposed to cancer-causing HPV types in their teens and early 20s. Unlike some other cancers, cervical cancer is not thought to be passed down through family genes.
Additionally, males can get HPV, too, causing anal cancer and genital warts in males.
Anyone who is allergic to the ingredients of Gardasil 9 including those severely allergic to yeast, should not receive the vaccine.
Gardasil 9 side effects include pain, swelling, redness, itching, bruising, bleeding, and a lump where your child got the shot, headache, fever, nausea, and dizziness.
Fainting can happen after getting Gardasil 9. Sometimes people who faint can fall and hurt themselves. For this reason, your health care professional may ask your child to sit or lie down for 15 minutes after your child gets Gardasil 9. Some people who faint might shake or become stiff.
May 31, 2019: A new study published in Science Direct, reported that within 10 years of HPV vaccine introduction, the vaccine-type HPV (VT) prevalence decreased 78 percent among 20 to 24-year-old women, and 38 percent in 25 to 29-year-old women.
Additionally, there were declines in both vaccinated and unvaccinated women, showing evidence of direct and herd protection.